Content
75%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
A well-structured, actionable immunogenomics analysis skill with a clear phased workflow and concrete tool guidance. The main gaps are some over-explained background immunology and the absence of an example for its own "write and run Python" directive.
Suggestions
Trim the Reasoning Strategy paragraph: drop the HLA-B27/abacavir/class-I-vs-II background that Claude already knows, keeping only the LOOK-UP-DON'T-GUESS directives and guiding principles.
Add one short copy-paste Python snippet under "COMPUTE, DON'T DESCRIBE" (e.g., loading IEDB/IMGT tool results into a pandas DataFrame for binding-affinity ranking) so the directive is immediately actionable.
Insert lightweight validation checkpoints between phases (e.g., after Phase 1/2, confirm the allele and binding data are non-empty and species-matched before proceeding) to raise workflow clarity.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | Mostly efficient with concrete tool specs and thresholds, but the Reasoning Strategy paragraph re-explains known immunology (HLA-B27/ankylosing spondylitis, abacavir/HLA-B*57:01, class I vs II biology) that could be trimmed. | 4 / 5 |
Actionability | Provides concrete tool names with explicit inputs/outputs and binding-affinity thresholds (IC50 < 50 nM strong), but the "COMPUTE, DON'T DESCRIBE" directive urging Python execution gives no runnable example to follow. | 4 / 5 |
Workflow Clarity | A clear 7-phase pipeline with ASCII flow, per-phase tools and workflows, plus recovery notes ("If allele not found: Check nomenclature"), though it lacks explicit inter-phase validation/checkpoint feedback loops. | 4 / 5 |
Progressive Disclosure | Well-organized single-file skill with clear section headers and navigation, no nested references; the substantial inlined phase-detail content is the only thing keeping it from a 5 for a no-bundle skill. | 4 / 5 |
Total | 16 / 20 Passed |